Aligos Therapeutics, Inc. Forms 3, 4 and 5: Preferred Stock
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 98 rows, 98 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2020-10-20: Reporting owner Novo Holdings A/S; Form 4; Security SERIES A CONVERTIBLE PREFERRED STOCK; Transaction C Conversion of derivative security.
- 2020-10-20: Reporting owner Novo Holdings A/S; Form 4; Security SERIES B -1 CONVERTIBLE PREFERRED STOCK; Transaction C Conversion of derivative security.
- 2020-10-20: Reporting owner Novo Holdings A/S; Form 4; Security SERIES B -2 CONVERTIBLE PREFERRED STOCK; Transaction C Conversion of derivative security.
- 2020-10-20: Reporting owner Wellington Biomedical Innovation Master Investors (Cayman) I L.P.; Form 4; Security Series B-1 convertible Preferred Stock; Transaction C Conversion of derivative security.
ALGS insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2020-10-20 | Novo Holdings A/S 10% Owner | 4 | SERIES A CONVERTIBLE PREFERRED STOCK Derivative · Direct | C Conversion of derivative security | −1,609,493 0 owned after | no price filed | $330.00 | 2020-10-22 |
| 2020-10-20 | Novo Holdings A/S 10% Owner | 4 | SERIES B -1 CONVERTIBLE PREFERRED STOCK Derivative · Direct | C Conversion of derivative security | −563,851 0 owned after | no price filed | $330.00 | 2020-10-22 |
| 2020-10-20 | Novo Holdings A/S 10% Owner | 4 | SERIES B -2 CONVERTIBLE PREFERRED STOCK Derivative · Direct | C Conversion of derivative security | −241,219 0 owned after | no price filed | $330.00 | 2020-10-22 |
| 2020-10-20 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% Owner | 4 | Series B-1 convertible Preferred Stock Derivative · Direct | C Conversion of derivative security | −1,335,048 0 owned after | $0.00 | $330.00 | 2020-10-22 |
| 2020-10-20 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% Owner | 4 | Series B-2 convertible Preferred Stock Derivative · Direct | C Conversion of derivative security | −571,143 0 owned after | $0.00 | $330.00 | 2020-10-22 |
| 2020-10-20 | Woiwode Thomas Director | 4 | Series A Preferred Stock Derivative · Indirect · See Footnote | C Conversion of derivative security | −2,145,991 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Woiwode Thomas Director | 4 | Series B-1 Preferred Stock Derivative · Indirect · See Footnote | C Conversion of derivative security | −198,839 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Woiwode Thomas Director | 4 | Series B-1 Preferred Stock Derivative · Indirect · See Footnote | C Conversion of derivative security | −463,959 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Woiwode Thomas Director | 4 | Series B-2 Preferred Stock Derivative · Indirect · See Footnote | C Conversion of derivative security | −85,065 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Woiwode Thomas Director | 4 | Series B-2 Preferred Stock Derivative · Indirect · See Footnote | C Conversion of derivative security | −198,485 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Vivo Capital Surplus Fund VIII, L.P. | Vivo Capital Fund VIII, L.P. | Vivo Capital VIII, LLC 10% Owner | 10% Owner | 10% Owner | 4 | Series A Preferred Stock Derivative · Indirect · Vivo Capital Fund VIII, L.P. | C Conversion of derivative security | −1,885,611 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Vivo Capital Surplus Fund VIII, L.P. | Vivo Capital Fund VIII, L.P. | Vivo Capital VIII, LLC 10% Owner | 10% Owner | 10% Owner | 4 | Series A Preferred Stock Derivative · Indirect · Vivo Capital Surplus Fund VIII, L.P. | C Conversion of derivative security | −260,380 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Vivo Capital Surplus Fund VIII, L.P. | Vivo Capital Fund VIII, L.P. | Vivo Capital VIII, LLC 10% Owner | 10% Owner | 10% Owner | 4 | Series B-1 Preferred Stock Derivative · Indirect · Vivo Capital Fund VIII, L.P. | C Conversion of derivative security | −523,726 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Vivo Capital Surplus Fund VIII, L.P. | Vivo Capital Fund VIII, L.P. | Vivo Capital VIII, LLC 10% Owner | 10% Owner | 10% Owner | 4 | Series B-1 Preferred Stock Derivative · Indirect · Vivo Capital Surplus Fund VIII, L.P. | C Conversion of derivative security | −72,320 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Vivo Capital Surplus Fund VIII, L.P. | Vivo Capital Fund VIII, L.P. | Vivo Capital VIII, LLC 10% Owner | 10% Owner | 10% Owner | 4 | Series B-2 Preferred Stock Derivative · Indirect · Vivo Capital Fund VIII, L.P. | C Conversion of derivative security | −224,054 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Vivo Capital Surplus Fund VIII, L.P. | Vivo Capital Fund VIII, L.P. | Vivo Capital VIII, LLC 10% Owner | 10% Owner | 10% Owner | 4 | Series B-2 Preferred Stock Derivative · Indirect · Vivo Capital Surplus Fund VIII, L.P. | C Conversion of derivative security | −30,939 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Versant Venture Capital VI, L.P. | Versant Vantage I, L.P. 10% Owner | 10% Owner | 4 | Series A Preferred Stock Derivative · Direct · (m) | C Conversion of derivative security | −2,145,991 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Versant Venture Capital VI, L.P. | Versant Vantage I, L.P. 10% Owner | 10% Owner | 4 | Series B-1 Preferred Stock Derivative · Direct · (m) | C Conversion of derivative security | −198,839 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Versant Venture Capital VI, L.P. | Versant Vantage I, L.P. 10% Owner | 10% Owner | 4 | Series B-1 Preferred Stock Derivative · Indirect · (m) | C Conversion of derivative security | −463,959 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Versant Venture Capital VI, L.P. | Versant Vantage I, L.P. 10% Owner | 10% Owner | 4 | Series B-2 Preferred Stock Derivative · Direct · (m) | C Conversion of derivative security | −85,065 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Versant Venture Capital VI, L.P. | Versant Vantage I, L.P. 10% Owner | 10% Owner | 4 | Series B-2 Preferred Stock Derivative · Indirect · (m) | C Conversion of derivative security | −198,485 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Symons Julian A. Officer (See Remarks) | 4 | Series A Preferred Stock Derivative · Direct | C Conversion of derivative security | −13,671 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Symons Julian A. Officer (See Remarks) | 4 | Series B-1 Preferred Stock Derivative · Direct | C Conversion of derivative security | −3,394 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Symons Julian A. Officer (See Remarks) | 4 | Series B-2 Preferred Stock Derivative · Direct | C Conversion of derivative security | −1,452 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Quan Lucinda Y. Officer (See Remarks) | 4 | Series A Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −6,835 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Quan Lucinda Y. Officer (See Remarks) | 4 | Series B-1 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −1,697 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Quan Lucinda Y. Officer (See Remarks) | 4 | Series B-2 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −726 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Nuechterlein Carole Director | 4 | Series A Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −2,145,991 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Nuechterlein Carole Director | 4 | Series B-1 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −662,799 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Nuechterlein Carole Director | 4 | Series B-2 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −283,550 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | BLATT LAWRENCE Officer (Chief Executive Officer) | 4 | Series A Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −41,016 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | BLATT LAWRENCE Officer (Chief Executive Officer) | 4 | Series A Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −122,601 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | BLATT LAWRENCE Officer (Chief Executive Officer) | 4 | Series A Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −13,671 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | BLATT LAWRENCE Officer (Chief Executive Officer) | 4 | Series A Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −13,671 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | BLATT LAWRENCE Officer (Chief Executive Officer) | 4 | Series B-1 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −50,712 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | BLATT LAWRENCE Officer (Chief Executive Officer) | 4 | Series B-1 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −3,394 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | BLATT LAWRENCE Officer (Chief Executive Officer) | 4 | Series B-1 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −3,394 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | BLATT LAWRENCE Officer (Chief Executive Officer) | 4 | Series B-2 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −21,695 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | BLATT LAWRENCE Officer (Chief Executive Officer) | 4 | Series B-2 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −1,452 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | BLATT LAWRENCE Officer (Chief Executive Officer) | 4 | Series B-2 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −1,452 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Beigelman Leonid Director, Officer (President) | 4 | Series A Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −163,842 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Beigelman Leonid Director, Officer (President) | 4 | Series A Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −13,559 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Beigelman Leonid Director, Officer (President) | 4 | Series A Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −13,559 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Beigelman Leonid Director, Officer (President) | 4 | Series B-1 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −50,781 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Beigelman Leonid Director, Officer (President) | 4 | Series B-1 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −3,359 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Beigelman Leonid Director, Officer (President) | 4 | Series B-1 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −3,359 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Beigelman Leonid Director, Officer (President) | 4 | Series B-2 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −21,724 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Beigelman Leonid Director, Officer (President) | 4 | Series B-2 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −1,437 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-20 | Beigelman Leonid Director, Officer (President) | 4 | Series B-2 Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −1,437 0 owned after | $0.00 | $330.00 | 2020-10-20 |
| 2020-10-15 holding as of filing | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% Owner | 3 | Series B-1 convertible Preferred Stock Derivative · Direct | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% Owner | 3 | Series B-2 convertible Preferred Stock Derivative · Direct | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Novo Holdings A/S 10% Owner | 3 | SERIES A CONVERTIBLE PREFERRED STOCK Derivative · Direct | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Novo Holdings A/S 10% Owner | 3 | SERIES B-1 CONVERTIBLE PREFERRED STOCK Derivative · Direct | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Novo Holdings A/S 10% Owner | 3 | SERIES B-2 CONVERTIBLE PREFERRED STOCK Derivative · Direct | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Woiwode Thomas Director | 3 | Series A Preferred Stock Derivative · Indirect · See Footnote | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Woiwode Thomas Director | 3 | Series B-1 Preferred Stock Derivative · Indirect · See Footnote | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Woiwode Thomas Director | 3 | Series B-1 Preferred Stock Derivative · Indirect · See Footnote | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Woiwode Thomas Director | 3 | Series B-2 Preferred Stock Derivative · Indirect · See Footnote | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Woiwode Thomas Director | 3 | Series B-2 Preferred Stock Derivative · Indirect · See Footnote | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Vivo Capital Surplus Fund VIII, L.P. | Vivo Capital VIII, LLC | Vivo Capital Fund VIII, L.P. 10% Owner | 10% Owner | 10% Owner | 3 | Series A Preferred Stock Derivative · Indirect · Vivo Capital Fund VIII, L.P. | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Vivo Capital Surplus Fund VIII, L.P. | Vivo Capital VIII, LLC | Vivo Capital Fund VIII, L.P. 10% Owner | 10% Owner | 10% Owner | 3 | Series A Preferred Stock Derivative · Indirect · Vivo Capital Surplus Fund VIII, L.P. | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Vivo Capital Surplus Fund VIII, L.P. | Vivo Capital VIII, LLC | Vivo Capital Fund VIII, L.P. 10% Owner | 10% Owner | 10% Owner | 3 | Series B-1 Preferred Stock Derivative · Indirect · Vivo Capital Fund VIII, L.P. | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Vivo Capital Surplus Fund VIII, L.P. | Vivo Capital VIII, LLC | Vivo Capital Fund VIII, L.P. 10% Owner | 10% Owner | 10% Owner | 3 | Series B-1 Preferred Stock Derivative · Indirect · Vivo Capital Surplus Fund VIII, L.P. | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Vivo Capital Surplus Fund VIII, L.P. | Vivo Capital VIII, LLC | Vivo Capital Fund VIII, L.P. 10% Owner | 10% Owner | 10% Owner | 3 | Series B-2 Preferred Stock Derivative · Indirect · Vivo Capital Fund VIII, L.P. | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Vivo Capital Surplus Fund VIII, L.P. | Vivo Capital VIII, LLC | Vivo Capital Fund VIII, L.P. 10% Owner | 10% Owner | 10% Owner | 3 | Series B-2 Preferred Stock Derivative · Indirect · Vivo Capital Surplus Fund VIII, L.P. | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Versant Venture Capital VI, L.P. | Versant Vantage I, L.P. 10% Owner | 10% Owner | 3 | Series A Preferred Stock Derivative · Direct · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Versant Venture Capital VI, L.P. | Versant Vantage I, L.P. 10% Owner | 10% Owner | 3 | Series B-1 Preferred Stock Derivative · Direct · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Versant Venture Capital VI, L.P. | Versant Vantage I, L.P. 10% Owner | 10% Owner | 3 | Series B-1 Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Versant Venture Capital VI, L.P. | Versant Vantage I, L.P. 10% Owner | 10% Owner | 3 | Series B-2 Preferred Stock Derivative · Direct · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Versant Venture Capital VI, L.P. | Versant Vantage I, L.P. 10% Owner | 10% Owner | 3 | Series B-2 Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Symons Julian A. Officer (See Remarks) | 3 | Series A Preferred Stock Derivative · Direct | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Symons Julian A. Officer (See Remarks) | 3 | Series B-1 Preferred Stock Derivative · Direct | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Symons Julian A. Officer (See Remarks) | 3 | Series B-2 Preferred Stock Derivative · Direct | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Quan Lucinda Y. Officer (See Remarks) | 3 | Series A Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Quan Lucinda Y. Officer (See Remarks) | 3 | Series B-1 Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Quan Lucinda Y. Officer (See Remarks) | 3 | Series B-2 Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Nuechterlein Carole Director | 3 | Series A Preferred Stock Derivative · Indirect · See Footnote | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Nuechterlein Carole Director | 3 | Series B-1 Preferred Stock Derivative · Indirect · See Footnote | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Nuechterlein Carole Director | 3 | Series B-2 Preferred Stock Derivative · Indirect · See Footnote | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | BLATT LAWRENCE Director, Officer (Chief Executive Officer) | 3 | Series A Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | BLATT LAWRENCE Director, Officer (Chief Executive Officer) | 3 | Series A Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | BLATT LAWRENCE Director, Officer (Chief Executive Officer) | 3 | Series A Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | BLATT LAWRENCE Director, Officer (Chief Executive Officer) | 3 | Series A Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | BLATT LAWRENCE Director, Officer (Chief Executive Officer) | 3 | Series B-1 Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | BLATT LAWRENCE Director, Officer (Chief Executive Officer) | 3 | Series B-1 Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | BLATT LAWRENCE Director, Officer (Chief Executive Officer) | 3 | Series B-1 Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | BLATT LAWRENCE Director, Officer (Chief Executive Officer) | 3 | Series B-2 Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | BLATT LAWRENCE Director, Officer (Chief Executive Officer) | 3 | Series B-2 Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | BLATT LAWRENCE Director, Officer (Chief Executive Officer) | 3 | Series B-2 Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Beigelman Leonid Director, Officer (President) | 3 | Series A Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Beigelman Leonid Director, Officer (President) | 3 | Series A Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Beigelman Leonid Director, Officer (President) | 3 | Series A Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Beigelman Leonid Director, Officer (President) | 3 | Series B-1 Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Beigelman Leonid Director, Officer (President) | 3 | Series B-1 Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Beigelman Leonid Director, Officer (President) | 3 | Series B-1 Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Beigelman Leonid Director, Officer (President) | 3 | Series B-2 Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Beigelman Leonid Director, Officer (President) | 3 | Series B-2 Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 | ||
| 2020-10-15 holding as of filing | Beigelman Leonid Director, Officer (President) | 3 | Series B-2 Preferred Stock Derivative · Indirect · (m) | Holding | no price filed | 2020-10-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |